Theoretically, the change in diagnosis from a cancer (noninvasive EFVPTC) to a non-cancer (NIFTP) should result in fewer total thyroidectomies. However, when we applied current guidelines on the reduced indications for completion thyroidectomy to the large proportion of patients who have contralateral disease (and therefore undergo total thyroidectomy initially), the potential impact of this change with regard to extent of surgery was limited to approximately 3.2% of patients with PTC compared with the projected potential impact on 18.6% of all patients with PTC worldwide. Thus, although we agree that an NIFTP diagnosis clearly has implications on oncologic outcomes, it is impossible to know whether the lobectomy group included a significantly greater proportion of NIFTP patients versus the total thyroidectomy group. While informative, an accurate estimation cannot be made based on the study by Rajjoub et al. 3 In this study, the authors included both NIFTP and invasive non-encapsulated FVPTC cases within their comparison group. In this context, FVPTC also encompasses both invasive encapsulated and invasive non-encapsulated FVPTC cases that are clinicopathologically distinct entities from NIFTP.
We look forward to future studies that prospectively characterize the molecular and oncologic behaviors of lowrisk PTC after meaningful exclusion of NIFTP. We appreciate the thoughtful commentary and the opportunity to respond.
